Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast Cancer
Open accessThe DOI matches its Crossref record.
Abstract
Purpose: To compare preoperative intense dose-dense (IDD) chemotherapy with conventionally scheduled preoperative chemotherapy in high-risk primary breast cancer (BC). Patients and Methods: In this randomized phase III trial a total of 668 eligible primary BC patients stratified for tumors ≥ 3 cm (n = 567) or inflammatory BC (n = 101) were randomly assigned to receive concurrent preoperative epirubicin/paclitaxel every 3 weeks or dose-dense and dose-escalated sequential epirubicin followed by paclitaxel every 2 weeks. All patients received three cycles of cyclophosphamide, methotrexate, and fluorouracil chemotherapy after surgery. Results: IDD treatment significantly improved pathologic complete response rate (18% v 10%; odds ratio [OR] 1.89; P = .008), disease-free survival (DFS; hazard ratio [HR], 0.71; P = .011), and overall survival (OS; HR, 0.83; P = .041) compared to epirubicin/paclitaxel. Patients with inflammatory BC had a particularly poor prognosis and did not appear to benefit from IDD therapy in this trial (DFS HR, 1.10; P = .739; OS HR, 1.25; P = .544). In contrast, patients with noninflammatory BC significantly benefited from IDD treatment (DFS HR, 0.65, P = .005; OS HR, 0.77, P = .013). Treatment effects in multivariate analysis were significant for noninflammatory BC (DFS HR, 0.65, P = .015; OS HR, 0.79, P = .034), but not for all patients (DFS HR, 0.76; P = .088; OS HR, 0.82; P = .059). IDD therapy was associated with significantly more nonhematologic toxicities, anemia, and thrombocytopenia, but with similar neutropenia and infection rates. Conclusion: Our results support the efficacy and short-term safety of IDD as preoperative chemotherapy. IDD was less well tolerated compared to standard treatment, but improved clinical outcomes in patients with noninflammatory high-risk primary BC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Self-citationvon Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Self-citationKaufmann, M., von Minckwitz, G., Mamounas, E. P., Cameron, D., Carey, L. A., Cristofanilli, M., Denkert, C., Eiermann, W., Gnant, M., Harris, J. R., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2108-2 · Cited by 482
Gray, R., Bradley, R., Braybrooke, J., Liu, Z., Peto, R., Davies, L., Dodwell, D., McGale, P., Pan, H., Taylor, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33137-4 · Cited by 400
Self-citationvon Minckwitz, G., Untch, M., Nüesch, E., Loibl, S., Kaufmann, M., Kümmel, S., Fasching, P. A., Eiermann, W., Blohmer, J.-U., Costa, S. D., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1228-x · Cited by 280
Self-citation
Metadata
- Authors
- Untch, M., Möbus, V., Kuhn, W., Muck, B. R., Thomssen, C., Bauerfeind, I., Harbeck, N., Werner, C., Lebeau, A., Schneeweiss, A., Kahlert, S., von Koch, F., Petry, K. U., Wallwiener, D., Kreienberg, R., Albert, U.-S., Lück, H.-J., Hinke, A., Jänicke, F., & Konecny, G. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-06-20
- Volume
- 27
- Issue
- 18
- Pages
- 2938-2945
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2111666200
- Cited by
- 149
- References
- 0
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast Cancer. https://app.cochat.ai/papers/10.1200/jco.2008.20.3133
- The paper
- Untch, M., Möbus, V., Kuhn, W., Muck, B. R., Thomssen, C., Bauerfeind, I., Harbeck, N., Werner, C., Lebeau, A., Schneeweiss, A., Kahlert, S., von Koch, F., Petry, K. U., Wallwiener, D., Kreienberg, R., Albert, U.-S., Lück, H.-J., Hinke, A., Jänicke, F., & Konecny, G. E. (2009). Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.20.3133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.